M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs
Yoshihiro Hayakawa,Manabu Kawada,Hiroyoshi Nishikawa,Hiroyoshi Nishikawa,Takahiro Ochiya,Takahiro Ochiya,Hideyuki Saya,Hideyuki Saya,Hiroyuki Seimiya,Hiroyuki Seimiya,Ryoji Yao,Ryoji Yao,Masahiro Hayashi,Chieko Kai,Chieko Kai,Akira Matsuda,Akira Matsuda,Tomoki Naoe,Atsushi Ohtsu,Atsushi Ohtsu,Taku Okazaki,Taku Okazaki,Hideo Saji,Hideo Saji,Masataka Sata,Masataka Sata,Haruhiko Sugimura,Haruhiko Sugimura,Yuichi Sugiyama,Masakazu Toi,Masakazu Toi,Tatsuro Irimura,Tatsuro Irimura +32 more
TL;DR: This review extensively summarize the effective use of many experimental cancer models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.
Journal ArticleDOI
Aromatase and aromatase inhibitors.
TL;DR: Preliminary studies con ducted in neoadjuvant setting indicated that aromatase inhibitors showed an extremely high response rate, which predicts a future paradigm, that neoadedjuvant therapy using aromat enzyme inhibitors singly or in combination may become standard for hormone-responsive and post-menopausal breast cancer patients.
Journal ArticleDOI
Neoadjuvant use of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by docetaxel (T) with concurrent COX-2 inhibitor in women with stage II/III breast cancer: A subanalysis of cardiac function.
TL;DR: This substudy is to evaluate the change in cardiac function of patients during treatment with preoperative FEC-T with concurrent celecoxib until and after surgery to evaluate changes in left ventricular ejection fraction (LVEF) across time.
Journal ArticleDOI
Development of Photoacoustic Mammography for Detection of Breast Cancer
Iku Yamaga,Yasufumi Asao,Masae Torii,Fakhrejahani Elham,Masahiro Takada,Toshiyuki Kitai,Shotaro Kanao,Masako Kataoka,Yoshiki Mikami,Tomoharu Sugie,Tsuyoshi Shiina,Masakazu Toi +11 more
TL;DR: PAM was used to evaluate 39 patients with 41 previously confirmed breast lesions before their surgical operations between August 2010 and March 2012 and it was suggested that PAM is a feasible technique for clinical practice.
Journal ArticleDOI
A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.
Noriyuki Masuda,Masakazu Toi,Takayuki Ueno,Takeharu Yamanaka,Shigetoyo Saji,Katsumasa Kuroi,Nobuaki Sato,Hiroyuki Takei,Yutaka Yamamoto,Shinji Ohno,Hiroko Yamashita,Kazufumi Hisamatsu,Kenjiro Aogi,H. Iwata,Hironobu Sasano +14 more
TL;DR: This is the first report that the 21-gene signature has value in predicting a response to neo-EXE therapy in postmenopausal pts with ER-positive breast cancer, and provides preliminary evidence for the clinical usefulness of the neoadjuvant treatment selection.